Pericardial Effusion Associated With Direct Oral Anticoagulant Use in a Single Center Experience
Authors' conclusion
This is the largest single center case series of DOAC PEff, with annual incidence higher than previously reported. Future research is needed to study the pharmacokinetic interactions between DOACs and commonly co-prescribed drugs as well as the cost-effectiveness of enhanced surveillance of PEff in those with solid cancer while on DOACs.
Study context
- Population
- Adult patients (age ≥18 years) with at least small to moderate pericardial effusion in the Santa Clara Health System between 2013 and 2023patients with at least small to moderate pericardial effusion (PEff)
- Participants
- 456 patients
- Exposure
- Factors associated with PEff
- Direct oral anticoagulant (DOAC) PEffn = 50
- Warfarin PEffn = 16
- NA PEffn = 390
- Outcome
- Annual incidence of PEff
Methodological detailsmultivariable logistic regression analysis
- Multivariable logistic regression analysis
Main finding
As reported in the abstract
Observational data: associations, not effects.
Further findings
Factors associated with moderately large or large PEff (logistic regression)
| OR (95% CI) | ||
|---|---|---|
| DOAC | 2.28 (1.19–4.37) | |
| Warfarin | 5.50 (1.88–16.06) | |
| Concurrent use of amiodarone | 4.32 (1.46–12.78) | |
| Presence of solid tumor | 2.06 (1.25–3.39) | |
| 0.050.21520Odds ratio (log scale) |
- Moderately large or large PEff among DOAC PEff cases
- 50% · Twenty-five of 50
Percutaneous or surgical drainage
- Cases that underwent either percutaneous or surgical drainage
- Twenty-one
Characteristics of DOAC PEff patients
- DOAC PEff patients significantly older and with more concurrent use of amiodarone
Original publication
Pericardial Effusion Associated With Direct Oral Anticoagulant Use in a Single Center Experience. JACC Adv. Published 17 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →